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PRECIS 
Successful conservative treatment for placenta accreta does not appear to compromise 
patients’ subsequent fertility or obstetric outcome, but the risk of recurrence is substantial.
FERTILITY AND PREGNANCY OUTCOMES AFTER CONSERVATIVE 
TREATMENT FOR PLACENTA ACCRETA  
ABSTRACT 
Objective: To estimate the fertility and pregnancy outcomes after successful conservative 
treatment for placenta accreta. 
Methods: This retrospective national multicenter study included women with a history of 
conservative management for placenta accreta in French university hospitals from 1993 
through 2007. Success of conservative treatment was defined by uterine preservation. Data 
were retrieved from medical files and telephone interviews.  
Results: Follow-up data were available for 96 (73.3%) of the 131 women included in the 
study. Eight women had severe intrauterine synechiae and were amenorrheic. Of the 27 
women who wanted more children, three women were attempting to become pregnant (mean 
duration: 11.7 months, range: 7-14 months), and 24 (88.9% [95% CI, 70.8-97.6%]) women 
had had 34 pregnancies (21 third-trimester deliveries, one ectopic pregnancy, two elective 
abortions, and 10 miscarriages) with a mean time to conception of 17.3 months (range, 2-48 
months). All 21 deliveries resulted in healthy babies born after 34 weeks of gestation. 
Placenta accreta recurred in 6 of 21 cases (28.6% [95% CI, 11.3-52.2%]) and was associated 
with placenta previa in 4 cases. Postpartum hemorrhage occurred in four (19.0% [95% CI, 
5.4-41.9%]) cases, related to placenta accreta in three and to uterine atony in one.  
Conclusions: Successful conservative treatment for placenta accreta does not appear to 
compromise the patients’ subsequent fertility or obstetric outcome. Nevertheless, these 
women should be advised of the high risk that placenta accreta may recur during future 
pregnancies.   
  
Key words: Placenta accreta or percreta, conservative treatment, embolization, fertility, 
pregnancy.   
INTRODUCTION 
Placenta accreta is a life-threatening condition characterized by placental villi abnormally 
adherent to the myometrium due to the absence or defects in the normal decidual basalis and 
the fibrinous Nitabuch layer [1]. In the past 30 years, the rate of placenta accreta has 
dramatically increased in conjunction with the rate of cesarean deliveries; it now occurs in 
developed countries at a frequency of 1 per 2,500 and has even been reported as often as 1 per 
530 deliveries [2-3]. Placenta accreta has become an important cause of maternal morbidity 
and mortality and is the leading cause of peripartum hysterectomy [4], failed vessel ligation 
[5-6], and failed pelvic arterial embolization [7]. The optimal management of placenta accreta 
remains a topic of debate. The extirpative approach, consisting in forcible manual removal of 
the placenta, is associated with massive hemorrhage and emergency hysterectomy [8-9]. 
Therefore, this option should be abandoned [8-9]. The approach most often recommended is a 
cesarean-hysterectomy, with no attempt to detach the placenta [10-11]. However, 
hysterectomy makes future childbearing impossible and is associated with significant 
morbidity in women with placenta accreta or percreta [8, 11]. Recent studies have shown the 
interest of attempting to preserve the uterus and avoid hysterectomy by leaving part or all of 
the adherent placenta in utero, thereby maintaining fertility and potentially minimizing 
complications [9, 11-12]. In a large national multicenter study we recently showed that this 
conservative treatment preserved the uterus in 78.4% (95% CI, 71.4-84.4%) of women, with a 
severe maternal morbidity rate of only 6% (95% CI, 2.9-10.7%) [12]. Although one of the 
main reason for choosing conservative treatment is the strong desire to remain fertile, almost 
nothing is known about fertility and pregnancy outcome in women who have undergone 
successful conservative management for placenta accreta [13-14]. The size and follow-up rate 
of these two small case series are limited, and they provided no information about the women 
who were presumably still fertile and desired more children but did not become pregnant. 
The aim of this study was to evaluate the impact on fertility and pregnancy outcome of 
successful conservative management for placenta accreta.  
 
  
   
MATERIALS AND METHODS 
This retrospective nationwide multicenter study was approved by our national Ethics 
Committee (Comité d'Ethique de la Recherche en Obstétrique et Gynecologie). Of 45 
obstetrics departments in tertiary hospitals in France, 40 agreed to participate and retrieved 
data from their databases about women who had successful conservative management for 
placenta accreta in their department from January 1993 through December 2007. Successful 
conservative treatment was defined by uterine preservation, i.e., the absence of either 
immediate or delayed hysterectomy due to placenta accreta. Therefore, women who 
underwent an immediate or delayed hysterectomy after the conservative treatment were 
excluded (n=36) [12]. The long-term maternal outcome of several of these women has been 
reported earlier [9, 13, 15]. We have previously described the diagnosis and management of 
placenta accreta [12]. Briefly, the clinical criteria for diagnosis were: 1) manual removal of 
the placenta was partially or totally impossible and there was no cleavage plane between part 
or all of the placenta and the uterus, and 2) the prenatal diagnosis of placenta accreta was 
confirmed by the failure of its gentle attempted removal during the third stage of labor. 
Conservative management followed the obstetrician's decision to leave the placenta in situ 
partially or totally, with no attempt to remove it forcibly. At the obstetrician's discretion and 
depending on the circumstances and course, additional treatment could include uterotonic 
drugs (oxytocin and/or sulprostone), prophylactic antibiotic therapy, methotrexate, 
preoperative ureteric stent placement, balloon catheter occlusion, and uterine 
devascularization procedures such as pelvic arterial embolization, surgical vessel ligation 
(uterine and/or hypogastric artery ligation and/or stepwise uterine devascularization), or 
uterine compression sutures (B-Lynch and Cho sutures). Stepwise uterine devascularization, 
as previously reported by AbdRabbo [16], consisted of normal and low bilateral uterine artery 
ligation, followed by bilateral utero-ovarian ligament ligation because of persistent 
hemorrhage [5-6, 17]. 
During April and June 2008, one of the authors (C.A.) attempted to contact all the women by 
telephone to determine the mid- and long-term outcome of conservative treatment. Women 
were asked about resumption of menses, their desire for subsequent pregnancies, attempts to 
conceive, and results. Mean time to conception was measured from the date at which the 
woman decided to attempt conception. Intrauterine synechiae were categorized, in accordance 
with the American Fertility Society classification, into three stages, that is, mild (stage I), 
moderate (stage II), and severe (stage III) [18]. Data about subsequent pregnancies came from 
the medical records or the attending physician. Descriptive characteristics were calculated for 
the variables of interest. Statistical analysis, including rates with their 95% confidence 
intervals, used StatXact.4 (Cytel Software Corporation, Cambridge, MA). 
 
 
 
 
 
RESULTS 
Of the 45 French university hospitals, 40 (88.9%) agreed to participate in the study, and 25 
had used conservative treatment at least once (range 1-46), treating 167 women. Of the 131 
women who had successful conservative management of placenta accreta and were included 
in the study, 96 (73.3%) women were successfully contacted at follow-up (range, 2-172 
months) (Figure 1). Follow-up information about the subsequent outcome of the placenta was 
available for 88 of these 96 (91.7%) women. In 75 (85.2%) cases, spontaneous placental 
resorption occurred, while hysteroscopic resection or curettage or both were used to remove 
the retained placenta in 13 cases (14.8%). 
Of the 96 women successfully contacted at follow-up, 88 had resumed menstruation. Severe 
intrauterine synechiae (stage III) were identified during ambulatory hysteroscopy in the eight 
women with amenorrhea. One of these eight women declined further treatment; hysteroscopic 
treatment of the synechiae was successful for six of the seven (Figure 1). Twelve other 
women, five complaining of decreased menstrual flow, and seven for routine reasons, also 
underwent outpatient hysteroscopy, which was normal in all cases. Nine non-amenorrheic 
women had voluntarily undergone ligation of fallopian tubes, so that only 85 (89.5%) women 
in this study remained fertile (Figure 1).  
Of these 85 women, 58 (68.3% [95% CI, 57.2-77.9%]), including the six women for whom 
severe intrauterine synechiae were successfully treated, did not want to become pregnant, at 
least in part because either the obstetrician 32.8% (19/58) [95% CI, 21.0-46.3%] and or the 
woman herself (22.4% (13/58) [95% CI, 12.5-35.3%] feared a recurrence of placenta accreta 
(Figure 1). 
None of the 27 women who wanted another pregnancy have thus far required an assisted 
reproductive procedure. Three women are currently trying to become pregnant (mean duration 
of attempt: 11.7 months, range, 7-14 months), whereas 24 (88.9% [95% CI, 70.8-97.6%]) 
women had already had 34 spontaneous pregnancies, with a mean time to conception of 17.3 
months (range, 2-48 months). Five (18.5) women took more than 24 months to become 
pregnant (women 4, 7, 8, 12, 14) (Table 1): one had a history of pregnancy following 
conservative treatment with a time to conception of 12 months (woman 12) (Table 1), two had 
a history of infertility requiring assisted reproductive procedures, and two women had a 
history of at least one pregnancy with a time to conception of more than 24 months. Of these 
34 pregnancies, 21 ended after 34 weeks' gestation, while 13 ended during the first trimester 
of pregnancy: two elective abortions (one due to the fear that placenta accreta would recur), 
one ectopic pregnancy treated by salpingotomy, and ten miscarriages, one complicated by a 
hemorrhage treated successfully by oxytocin (Figure 1).  
Table 1 summarizes the characteristics of the 21 pregnancies delivered during the third 
trimester. Eighteen women gave birth to 21 healthy singletons. Only one had a low birth 
weight for gestational age (case 15) (see below). Delivery was moderately preterm for four 
(19.0% [95% CI, 5.4-41.9%]), because of preeclampsia associated with intrauterine growth 
restriction in a woman with a history of preeclampsia (case 15), bleeding in a woman with 
placenta previa (case 8), premature rupture of membranes (case 6), and elective cesarean in a 
woman with suspected placenta accreta (case 5). 
Placenta accreta recurred in 6 of 21 cases (28.6% [95% CI, 11.3-52.2%]) and was associated 
with placenta previa in 4 cases. In four of these six cases, the placenta accreta was managed 
successfully by conservative treatment, in one case by a cesarean and hysterectomy, and in 
one case by unsuccessful extirpative treatment followed by a peripartum hysterectomy (Table 
1). Postpartum hemorrhage occurred in four (19.0% [95% CI, 5.4-41.9%]) women, related to 
placenta accreta in three cases and to uterine atony in one.  
DISCUSSION 
Placenta accreta is thought to be due to an absence or deficiency of Nitabuch’s layer or the 
decidua spongiosa, following the failure of the endometrium/decidua basalis to re-form after 
trauma to the endometrium from surgical procedures [19]. The pathophysiology of placenta 
accreta is therefore similar to that of intrauterine synechiae, based as it is on endometrial 
alteration that might promote abnormal implantation, resulting in infertility, miscarriage, or 
recurrent placenta accreta [19]. Hypothetically, conservative treatment might worsen the 
endometrial disease, due to more uterine scars (i.e., by cesarean), uterine devascularization 
procedures (i.e., embolization or surgical vessel ligation), or clinical or subclinical uterine 
infection. Our results are therefore reassuring and suggest that successful conservative 
treatment for placenta accreta does not appear to compromise the patients’ subsequent fertility 
or obstetric outcome, but that the risk of placenta accreta recurrence during future deliveries is 
high.  
However, we found severe intrauterine synechiae, known to affect fertility adversely, in the 
eight women who did not resume menstruation among the 96 women followed up after 
successful conservative treatment. Fertility was clearly altered in the two women for whom 
synechiae were not removed. Fertility outcome could not be determined for the remaining six 
women whose severe synechiae were successfully treated, because none wanted another child. 
This relatively high rate of synechiae following placenta accreta is consistent with a previous 
smaller and more limited study that suggested that placenta accreta might be a risk factor for 
synechiae [20]. Moreover, the frequency of intrauterine synechia in the group presumed 
fertile is probably underestimated: mild or moderate synechiae are frequently asymptomatic, 
and hysteroscopy was not performed routinely for women after conservative treatment. 
Subclinical synechiae or endometrial diseases may be one of the factors responsible for the 
high number of miscarriages observed in our study (10 for 34 pregnancies) and may result in 
implantation failure.  
The 21 subsequent third-trimester pregnancies resulted in 21 healthy babies, with normal birth 
weight for age, except for one whose mother had current and past preeclampsia. The absence 
of pregnancy complications observed in our study, except for abnormal placentation and 
postpartum hemorrhage, is consistent with the few previous reports on pregnancy after 
conservative treatment for placenta accreta [13-15].  
Moreover, no adverse neonatal outcome was observed in women who underwent additional 
embolization or vessel ligation (n=7) with the conservative treatment. This result is also 
consistent with the literature, as previous reports suggest that neither vessel ligation [5, 21] 
nor pelvic arterial embolization [20, 22] compromises subsequent obstetric outcome.  
Although neonatal outcome was favorable for all the pregnancies, the recurrence rate of 
placenta accreta was high (28.6%). This result is consistent with the literature review 
performed by Alanis et al. [14]. The high rate of recurrence is not surprising, for all the 
women had acquired risk factors for abnormal placentation that resulted in the history of 
placenta accreta required for inclusion in this study. Furthermore, still other risk factors for 
placenta accreta (age > 35 years, additional cesarean delivery, previous history of placenta 
accreta) were added to the previous ones. We cannot rule out the possibility that this high rate 
of recurrent placenta accreta was also related, at least in part, to the uterine devascularization 
procedures performed as part of the conservative treatment. It has been suggested that 
implantation and trophoblast invasion in subsequent pregnancies may be modified in a uterus 
previously devascularized, either by stepwise uterine devascularization [5] or pelvic arterial 
embolization [20-21]. Nevertheless, interestingly, in our study, placenta accreta recurred in 
only 2 of the 7 women who had undergone an additional uterine devascularization procedure 
concomitantly with the previous conservative treatment.  
We might speculate that relatively few parous women who have undergone conservative 
treatment and therefore also close monitoring for several months would want another child, 
especially in view of the potential risk of another episode of placenta accreta. Our study 
shows that this percentage is not that low (31.7%; 27/85). It is even higher (36.5%; 27/74) if 
we do not consider the women who reported it was too soon after their last delivery to become 
pregnant again (n=11). Interestingly, the primary reason that women decided against another 
pregnancy was that their obstetrician strongly recommended against it. Nevertheless, the 
second leading reason was the woman's own fear of a recurrence of placenta accreta. Four 
earlier studies report similar results: women with a history of severe postpartum hemorrhage 
requiring pelvic arterial embolization and/or uterine-sparing surgical procedures are likely to 
decide against another pregnancy because of their fear of another hemorrhage [5, 20-22].  
Several limitations of our study must be underlined. The first is its retrospective design, 
common to all studies that have thus far assessed maternal outcome after placenta accreta. 
Accordingly, all the flaws of retrospective analyses apply. In particular, some eligible cases 
may not have been detected. Second, 26.7% of eligible women were lost to follow-up during 
this 15-year period study. Third, it is possible that some women did not actually have placenta 
accreta; pathological confirmation is of course impossible after successful conservative 
treatment, i.e., in cases without a hysterectomy specimen [12]. Nevertheless, our results 
reflect the long-term consequences in real life of conservative treatment for placenta accreta.  
In conclusion, our study suggests that successful conservative treatment for placenta accreta 
does not appear to compromise the patients’ subsequent fertility or obstetric outcome. Women 
who want another pregnancy should, however, be advised that the risk of recurrence is high.  
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